Drugs / BPI-28592
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05302843 | Mar 2021 → Dec 2023 | metastatic neoplasm | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-06-23 | Betta Pharmaceuticals Co., Ltd. | Results 贝达药业自主研发成果BPI-23314和BPI-28592初登2020 AACR bettapharma.com ↗
BPI-28592是一个新的化学实体，对各种原发TRK融合蛋白具有亚纳摩尔水平的效价。 |
| 2020-04-29 | Betta Pharmaceuticals Co., Ltd. | Regulatory 贝达药业在研新药BPI-28592获批开展临床试验 bettapharma.com ↗
公司自主研发的TRK抑制剂BPI-28592片的药品临床试验申请获得批准。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-23 | Betta Pharmaceuticals Co., Ltd. | 贝达药业自主研发成果BPI-23314和BPI-28592初登2020 AACR bettapharma.com ↗ |
| 2020-04-29 | Betta Pharmaceuticals Co., Ltd. | 贝达药业在研新药BPI-28592获批开展临床试验 bettapharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-28592 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05302843 ↗ |
| Action | Inhibit | “Biochemical assays showed strong inhibition and high selectivity against TRKA, TRKB, and TRKC.” PMID 39256512 ↗ Sep 2024 |
| Route | Oral | “Patients receive BPI-28592 PO.” NCT05302843 ↗ |